Biontech And Oncoc4 Announce Clinically Meaningful Overall Survival Benefit For Lung Cancer Drug

Reuters12-08 15:05

Dec 8 (Reuters) - Biontech<22UAy.DE> said on Saturday::
*BIONTECH AND ONCOC4 ANNOUNCE CLINICALLY MEANINGFUL OVERALL SURVIVAL BENEFIT FOR SELECTIVE TREG MODULATOR GOTISTOBART IN PATIENTS WITH PREVIOUSLY TREATED SQUAMOUS NON-SMALL CELL LUNG CANCER
*GOTISTOBART SHOWED A REDUCTION IN THE RISK OF DEATH BY MORE THAN HALF COMPARED TO STANDARD OF CARE CHEMOTHERAPY
*GOTISTOBART WAS GRANTED FAST TRACK DESIGNATION BY THE U.S. FOOD AND DRUG ADMINISTRATION (“FDA”)
*GRADE ≥3 TREATMENT-RELATED ADVERSE EVENTS (“AES”) WERE REPORTED IN 19/45 (42.2%) PATIENTS IN THE GOTISTOBART TREATMENT ARM VERSUS 20/41 (48.8%) PATIENTS IN DOCETAXEL TREATMENT ARM
* Further company coverage: [<22UAy.DE>]
* (Gdansk Newsroom)
* ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))

((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))
Source Date/Time = 08-DEC-202506:54:27 GMT

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2589917382?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-08 15:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2589917382","market":"us","top_or_hot":-1,"title":"Biontech And Oncoc4 Announce Clinically Meaningful Overall Survival Benefit For Lung Cancer Drug","media":"Reuters","content":"<html><body>Dec 8 (Reuters) - Biontech&lt;22UAy.DE&gt; said on Saturday::<br/>*BIONTECH AND ONCOC4 ANNOUNCE CLINICALLY MEANINGFUL OVERALL SURVIVAL BENEFIT FOR SELECTIVE TREG MODULATOR GOTISTOBART IN PATIENTS WITH PREVIOUSLY TREATED SQUAMOUS NON-SMALL CELL LUNG CANCER<br/>*GOTISTOBART SHOWED A REDUCTION IN THE RISK OF DEATH BY MORE THAN HALF COMPARED TO STANDARD OF CARE CHEMOTHERAPY<br/>*GOTISTOBART WAS GRANTED FAST TRACK DESIGNATION BY THE U.S. FOOD AND DRUG ADMINISTRATION (“FDA”) <br/>*GRADE ≥3 TREATMENT-RELATED ADVERSE EVENTS (“AES”) WERE REPORTED IN 19/45 (42.2%) PATIENTS IN THE GOTISTOBART TREATMENT ARM VERSUS 20/41 (48.8%) PATIENTS IN DOCETAXEL TREATMENT ARM<br/>* Further company coverage: [&lt;22UAy.DE&gt;] <br/>* (Gdansk Newsroom)<br/>* ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))<br/><br/>  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))<br/>  Source Date/Time = 08-DEC-202506:54:27 GMT</body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biontech And Oncoc4 Announce Clinically Meaningful Overall Survival Benefit For Lung Cancer Drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiontech And Oncoc4 Announce Clinically Meaningful Overall Survival Benefit For Lung Cancer Drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-08 15:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body>Dec 8 (Reuters) - Biontech&lt;22UAy.DE&gt; said on Saturday::<br/>*BIONTECH AND ONCOC4 ANNOUNCE CLINICALLY MEANINGFUL OVERALL SURVIVAL BENEFIT FOR SELECTIVE TREG MODULATOR GOTISTOBART IN PATIENTS WITH PREVIOUSLY TREATED SQUAMOUS NON-SMALL CELL LUNG CANCER<br/>*GOTISTOBART SHOWED A REDUCTION IN THE RISK OF DEATH BY MORE THAN HALF COMPARED TO STANDARD OF CARE CHEMOTHERAPY<br/>*GOTISTOBART WAS GRANTED FAST TRACK DESIGNATION BY THE U.S. FOOD AND DRUG ADMINISTRATION (“FDA”) <br/>*GRADE ≥3 TREATMENT-RELATED ADVERSE EVENTS (“AES”) WERE REPORTED IN 19/45 (42.2%) PATIENTS IN THE GOTISTOBART TREATMENT ARM VERSUS 20/41 (48.8%) PATIENTS IN DOCETAXEL TREATMENT ARM<br/>* Further company coverage: [&lt;22UAy.DE&gt;] <br/>* (Gdansk Newsroom)<br/>* ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))<br/><br/>  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))<br/>  Source Date/Time = 08-DEC-202506:54:27 GMT</body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4548","symbol_name":"巴美列捷福持仓","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nRSDblqzx3:1","article_id":"2589917382","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2589917382","pubTimestamp":1765177538,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Dec 8 (Reuters) - Biontech<22UAy.DE> said on Saturday::*BIONTECH AND ONCOC4 ANNOUNCE CLINICALLY MEANINGFUL OVERALL SURVIVAL BENEFIT FOR SELECTIVE TREG MODULATOR GOTISTOBART IN PATIENTS WITH PREVIOUSLY","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4548":"巴美列捷福持仓","BK4535":"淡马锡持仓","BK4568":"美国抗疫概念","BK4139":"生物科技","BK4551":"寇图资本持仓","BNTX":"BioNTech SE","BK4588":"碎股","BK4585":"ETF&股票定投概念"},"translate_title":"Biontech和Oncoc4宣布肺癌药物具有临床意义的总生存获益","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BNTX":0.9},"content_text":"Dec 8 (Reuters) - Biontech<22UAy.DE> said on Saturday::*BIONTECH AND ONCOC4 ANNOUNCE CLINICALLY MEANINGFUL OVERALL SURVIVAL BENEFIT FOR SELECTIVE TREG MODULATOR GOTISTOBART IN PATIENTS WITH PREVIOUSLY TREATED SQUAMOUS NON-SMALL CELL LUNG CANCER*GOTISTOBART SHOWED A REDUCTION IN THE RISK OF DEATH BY MORE THAN HALF COMPARED TO STANDARD OF CARE CHEMOTHERAPY*GOTISTOBART WAS GRANTED FAST TRACK DESIGNATION BY THE U.S. FOOD AND DRUG ADMINISTRATION (“FDA”) *GRADE ≥3 TREATMENT-RELATED ADVERSE EVENTS (“AES”) WERE REPORTED IN 19/45 (42.2%) PATIENTS IN THE GOTISTOBART TREATMENT ARM VERSUS 20/41 (48.8%) PATIENTS IN DOCETAXEL TREATMENT ARM* Further company coverage: [<22UAy.DE>] * (Gdansk Newsroom)* ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 08-DEC-202506:54:27 GMT","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.10","shortVersion":"4.35.10","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2589917382","isCrawlerRequest":true}